Interim results highlight benefits of RGX-202 for Duchenne muscular dystrophy
- Positive interim data from Phase III trial
- Focus on Duchenne muscular dystrophy
- RGX-202 shows promising outcomes
Regenxbio has released interim results from its Phase III AFFINITY trial, which evaluates RGX-202 for the treatment of Duchenne muscular dystrophy (DMD). The findings indicate significant potential benefits in improving muscle strength and function in participants. This trial represents a crucial step towards innovative therapies for DMD, a genetic disorder characterized by progressive muscle degeneration.
The interim data demonstrates that RGX-202 produced favorable outcomes related to muscle strength, as measured by the North Star Ambulatory Assessment. An ongoing focus of the trial is to ascertain the long-term efficacy and safety of this gene therapy approach. Regenxbio's commitment to advancing treatment options for DMD underscores the urgency of addressing the needs of affected individuals and their families.
As DMD impacts boys predominantly, the need for effective therapeutic options is substantial. The early results from the trial are being closely monitored by the medical community as Regenxbio progresses towards further analysis and potential regulatory discussions. The focus remains on providing hope and improved quality of life to those living with this condition.
